Longitudinal Bile Acid Composition Changes Following Faecal Microbiota Transplantation for Clostridioides difficile Infection in Children With and Without Underlying Inflammatory Bowel Disease. 2023

Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
Division of Gastroenterology and Hepatology, New York University Grossman School of Medicine, New York, NY, USA.

OBJECTIVE Faecal microbiota transplant [FMT] is effective in treating recurrent Clostridioides difficile infection [CDI] and restores gut microbiota composition. This is unlikely to account for its entire mechanism of efficacy, as studies have shown that factors such as bile acids influence the risk of infection by affecting Clostridioides difficile germination. We therefore aimed to investigate longitudinal changes in the gut bile acid composition after FMT performed for recurrent CDI, in children with and without inflammatory bowel disease [IBD]. METHODS Eight children received FMT; five had underlying IBD. Primary and secondary faecal bile acids were measured by liquid chromatography-mass spectrometry in recipients [pre-FMT and longitudinally post-FMT for up to 6 months] and donors. RESULTS Pre-FMT, recipients had higher primary and lower secondary bile acid proportions compared with donors. Post-FMT, there was a gradual increase of secondary and decrease of primary bile acids. Whereas gut bacterial diversity had been shown to be restored in all children shortly after FMT, normalisation of bile acids to donor levels occurred only by 6 months. In children with IBD, although microbiota diversity returned to pre-FMT levels within 6 months, secondary bile acids remained at donor levels. CONCLUSIONS The differences in bile acid profiles compared with gut bacterial diversity post-FMT suggests that interactions between the two may be more complex than previously appreciated and may contribute to FMT efficacy in different ways. This initial finding demonstrates the need to further investigate gut metabolites in larger cohorts, with longitudinal sampling to understand the mechanisms of FMT effectiveness.

UI MeSH Term Description Entries
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003015 Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species. Clostridioides Infections,Clostridioides difficile Infection,Clostridioides perfringens Food Poisoning,Clostridioides perfringens Infections,Clostridioides sordellii Infection,Clostridium difficile Infections,Clostridium sordellii Infections,Clostridium difficile Infection,Clostridium perfringens Food Poisoning,Clostridium perfringens Infections,Clostridium sordellii Infection,Infections, Clostridium,Clostridioides Infection,Clostridioides perfringens Infection,Clostridium Infection,Clostridium perfringens Infection,Infection, Clostridioides difficile,Infection, Clostridioides sordellii,Infection, Clostridium,Infection, Clostridium difficile,Infection, Clostridium sordellii
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069467 Fecal Microbiota Transplantation Transfer of GASTROINTESTINAL MICROBIOTA from one individual to another by infusion of donor FECES to the upper or lower GASTROINTESTINAL TRACT of the recipient. Fecal Microbiome Transplantation,Fecal Microbiota Transfer,Fecal Microbiota Transplant,Intestinal Microbiome Transfer,Intestinal Microbiome Transplant,Intestinal Microbiome Transplantation,Intestinal Microbiota Transplant,Intestinal Microbiota Transplantation,Donor Feces Infusion,Fecal Transplant,Fecal Transplantation,Intestinal Microbiota Transfer,Donor Feces Infusions,Fecal Microbiome Transplantations,Fecal Microbiota Transfers,Fecal Microbiota Transplantations,Fecal Microbiota Transplants,Fecal Transplantations,Fecal Transplants,Feces Infusion, Donor,Feces Infusions, Donor,Infusion, Donor Feces,Infusions, Donor Feces,Intestinal Microbiome Transfers,Intestinal Microbiome Transplantations,Intestinal Microbiome Transplants,Intestinal Microbiota Transfers,Intestinal Microbiota Transplantations,Intestinal Microbiota Transplants,Microbiome Transfer, Intestinal,Microbiome Transfers, Intestinal,Microbiome Transplant, Intestinal,Microbiome Transplantation, Fecal,Microbiome Transplantation, Intestinal,Microbiome Transplantations, Fecal,Microbiome Transplantations, Intestinal,Microbiome Transplants, Intestinal,Microbiota Transfer, Fecal,Microbiota Transfer, Intestinal,Microbiota Transfers, Fecal,Microbiota Transfers, Intestinal,Microbiota Transplant, Fecal,Microbiota Transplant, Intestinal,Microbiota Transplantation, Fecal,Microbiota Transplantation, Intestinal,Microbiota Transplantations, Fecal,Microbiota Transplantations, Intestinal,Microbiota Transplants, Fecal,Microbiota Transplants, Intestinal,Transfer, Fecal Microbiota,Transfer, Intestinal Microbiome,Transfer, Intestinal Microbiota,Transfers, Fecal Microbiota,Transfers, Intestinal Microbiome,Transfers, Intestinal Microbiota,Transplant, Fecal,Transplant, Fecal Microbiota,Transplant, Intestinal Microbiome,Transplant, Intestinal Microbiota,Transplantation, Fecal,Transplantation, Fecal Microbiome,Transplantation, Fecal Microbiota,Transplantation, Intestinal Microbiome,Transplantation, Intestinal Microbiota,Transplantations, Fecal,Transplantations, Fecal Microbiome,Transplantations, Fecal Microbiota,Transplantations, Intestinal Microbiome,Transplantations, Intestinal Microbiota,Transplants, Fecal,Transplants, Fecal Microbiota,Transplants, Intestinal Microbiome,Transplants, Intestinal Microbiota
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001647 Bile Acids and Salts Steroid acids and salts. The primary bile acids are derived from cholesterol in the liver and usually conjugated with glycine or taurine. The secondary bile acids are further modified by bacteria in the intestine. They play an important role in the digestion and absorption of fat. They have also been used pharmacologically, especially in the treatment of gallstones. Bile Acid,Bile Salt,Bile Salts,Bile Acids,Acid, Bile,Acids, Bile,Salt, Bile,Salts, Bile
D015212 Inflammatory Bowel Diseases Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. Bowel Diseases, Inflammatory,Inflammatory Bowel Disease
D016360 Clostridioides difficile A common inhabitant of the colon flora in human infants and sometimes in adults. The type species Clostridioides difficile is formerly known as Clostridium difficile. It is a causative agent for CLOSTRIDIOIDES INFECTIONS and is associated with PSEUDOMEMBRANOUS ENTEROCOLITIS in patients receiving antibiotic therapy. Clostridium difficile
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
August 2018, BMC gastroenterology,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
June 2022, Journal of Crohn's & colitis,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
May 2023, Journal of Crohn's & colitis,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
January 2020, Medicina,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
January 2020, Journal of inflammation research,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
October 2020, Inflammatory bowel diseases,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
January 2018, Gastroenterology and hepatology from bed to bench,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
February 2023, The lancet. Gastroenterology & hepatology,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
February 2023, The lancet. Gastroenterology & hepatology,
Lea Ann Chen, and Maria Oliva-Hemker, and Arielle Radin, and Melissa Weidner, and Brynn D O'Laughlin, and Cynthia L Sears, and Norman B Javitt, and Suchitra K Hourigan
February 2023, The lancet. Gastroenterology & hepatology,
Copied contents to your clipboard!